Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Glasmacher

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Supportive Cancer Therapy|July 17, 2008
Invasive fungal infections in patients with hematologic malignancies: the next stepsAxel Glasmacher
Cancer Treatment Reviews|April 3, 2003
High dose therapy may have no survival benefit over CHOEP primary chemotherapy for people with aggressive non-Hodgkin's lymphomaAxel Glasmacher
Cancer Treatment Reviews|August 25, 2004
Initial high dose chemotherapy plus autologous stem cell support improves survival outcomes compared with a standard CHOP regimen in people with higher intermediate risk aggressive lymphomaAxel Glasmacher
Mycoses|June 29, 2005
Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofunginGeorg Maschmeyer, Axel Glasmacher
Cancer Treatment Reviews|February 10, 2004
Vancomycin does not benefit persistently febrile neutropenic people with cancerJames C Wade, Axel Glasmacher
The Journal of Antimicrobial Chemotherapy|August 27, 2005
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignanciesAxel Glasmacher, Archibald Grant Prentice
The Journal of Antimicrobial Chemotherapy|August 27, 2005
Making sense of itraconazole pharmacokineticsArchibald Grant Prentice, Axel Glasmacher
Acta Haematologica|September 17, 2005
The current status of thalidomide in the management of multiple myelomaAxel Glasmacher, Marie von Lilienfeld-Toal
Lancet (London, England)|May 4, 2002
Priority-setting decisions for new cancer drugsKeith Wheatley, Benjamin Djulbegovic, Axel Glasmacher
Cancer|December 22, 2004
Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort studyMarie von Lilienfeld-Toal, Axel Glasmacher
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Supportive Cancer Therapy|July 17, 2008
Invasive fungal infections in patients with hematologic malignancies: the next stepsAxel Glasmacher
Cancer Treatment Reviews|April 3, 2003
High dose therapy may have no survival benefit over CHOEP primary chemotherapy for people with aggressive non-Hodgkin's lymphomaAxel Glasmacher
Cancer Treatment Reviews|August 25, 2004
Initial high dose chemotherapy plus autologous stem cell support improves survival outcomes compared with a standard CHOP regimen in people with higher intermediate risk aggressive lymphomaAxel Glasmacher
Mycoses|June 29, 2005
Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofunginGeorg Maschmeyer, Axel Glasmacher
Cancer Treatment Reviews|February 10, 2004
Vancomycin does not benefit persistently febrile neutropenic people with cancerJames C Wade, Axel Glasmacher
The Journal of Antimicrobial Chemotherapy|August 27, 2005
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignanciesAxel Glasmacher, Archibald Grant Prentice
The Journal of Antimicrobial Chemotherapy|August 27, 2005
Making sense of itraconazole pharmacokineticsArchibald Grant Prentice, Axel Glasmacher
Acta Haematologica|September 17, 2005
The current status of thalidomide in the management of multiple myelomaAxel Glasmacher, Marie von Lilienfeld-Toal
Lancet (London, England)|May 4, 2002
Priority-setting decisions for new cancer drugsKeith Wheatley, Benjamin Djulbegovic, Axel Glasmacher
Cancer|December 22, 2004
Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort studyMarie von Lilienfeld-Toal, Axel Glasmacher
Pageof 8